Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Overview of attention for article published in Nature Medicine, October 2022

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 X post from an account with 467 followers.

New article: Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial https://t.co/w1OEJhvqwM #parkinsons #neurology https://t.co/JhRASE0ZpK

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.